X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (243) 243
Publication (32) 32
Newspaper Article (6) 6
Book / eBook (3) 3
Book Review (2) 2
Book Chapter (1) 1
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (77) 77
index medicus (70) 70
female (48) 48
male (46) 46
oncology (43) 43
aged (35) 35
middle aged (35) 35
adult (31) 31
cancer (27) 27
article (26) 26
aged, 80 and over (23) 23
chemotherapy (20) 20
india (17) 17
survival (16) 16
head and neck cancer (15) 15
research (15) 15
analysis (14) 14
care and treatment (14) 14
cetuximab (14) 14
groundwater (14) 14
radiation (14) 14
head and neck neoplasms - drug therapy (13) 13
human-papillomavirus (13) 13
radon (13) 13
risk (13) 13
squamous cell carcinoma (13) 13
antineoplastic agents - therapeutic use (12) 12
head and neck neoplasms - pathology (12) 12
hematology, oncology and palliative medicine (12) 12
kaplan-meier estimate (12) 12
lung cancer (12) 12
studies (12) 12
treatment outcome (12) 12
carcinoma, squamous cell - drug therapy (11) 11
carcinoma, squamous cell - pathology (11) 11
drinking water (11) 11
head (11) 11
immunology (11) 11
mutation (11) 11
prognosis (11) 11
resistance (11) 11
squamous cell carcinoma of head and neck (11) 11
uranium (11) 11
carcinoma, squamous cell - mortality (10) 10
head and neck neoplasms - mortality (10) 10
immunotherapy (10) 10
metastasis (10) 10
punjab (10) 10
radiotherapy (10) 10
squamous-cell carcinoma (10) 10
tumors (10) 10
annual effective dose (9) 9
expression (9) 9
head and neck neoplasms - metabolism (9) 9
risk factors (9) 9
biomarkers (8) 8
carcinoma, squamous cell - metabolism (8) 8
carcinoma, squamous cell - therapy (8) 8
disease-free survival (8) 8
health aspects (8) 8
ingestion (8) 8
lung-cancer (8) 8
patients (8) 8
pembrolizumab (8) 8
public, environmental & occupational health (8) 8
radiology, nuclear medicine & medical imaging (8) 8
retrospective studies (8) 8
surgery (8) 8
animals (7) 7
antibodies, monoclonal, humanized (7) 7
earth sciences (7) 7
genes (7) 7
haplotypes (7) 7
head and neck neoplasms - therapy (7) 7
neck (7) 7
neoplasm recurrence, local - drug therapy (7) 7
neoplasm staging (7) 7
oropharyngeal cancer (7) 7
susceptibility (7) 7
toxicity (7) 7
alleles (6) 6
cancer therapies (6) 6
carcinoma, non-small-cell lung - genetics (6) 6
cell biology (6) 6
cisplatin (6) 6
cohort studies (6) 6
disease progression (6) 6
drinking-water (6) 6
energy & fuels (6) 6
environmental sciences (6) 6
exposure (6) 6
follow-up studies (6) 6
gene expression (6) 6
geology (6) 6
geosciences, multidisciplinary (6) 6
head and neck neoplasms - radiotherapy (6) 6
head and neck neoplasms - virology (6) 6
himachal-pradesh (6) 6
hpv (6) 6
immunohistochemistry (6) 6
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. e510 - e521
Summary The incidence of brain metastases has increased as a result of improved systemic control and advances in imaging. However, development of novel... 
Hematology, Oncology and Palliative Medicine | ANAPLASTIC LYMPHOMA KINASE | PROPHYLACTIC CRANIAL IRRADIATION | ONCOLOGY | BARRIER PERMEABILITY | LEPTOMENINGEAL CARCINOMATOSIS | ACQUIRED-RESISTANCE | HIGH-DOSE CRIZOTINIB | NERVOUS-SYSTEM PROGRESSION | INHIBITOR CRIZOTINIB | ANTITUMOR-ACTIVITY | TUMOR VASCULATURE | Capillary Permeability | Humans | Tumor Microenvironment | Drug Resistance, Neoplasm | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Antineoplastic Agents - metabolism | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Biomarkers, Tumor - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Biomarkers, Tumor - antagonists & inhibitors | Radiotherapy, Adjuvant | Lung Neoplasms - genetics | Brain Neoplasms - enzymology | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Carcinoma, Non-Small-Cell Lung - genetics | Brain Neoplasms - genetics | Brain Neoplasms - drug therapy | Receptor Protein-Tyrosine Kinases - metabolism | Blood-Brain Barrier - metabolism | Phenotype | Animals | Receptor Protein-Tyrosine Kinases - genetics | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Protein Kinase Inhibitors - metabolism | Therapeutics | Permeability | Metastasis | Drug resistance | Lung cancer, Non-small cell | Homeopathy | Materia medica and therapeutics
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 4, pp. 452 - 463
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2014, Volume 370, Issue 13, pp. 1189 - 1197
Ceritinib is 20 times as potent as crizotinib at inhibiting anaplastic lymphoma kinase (ALK) in vitro. In patients, ceritinib produced antitumor responses in... 
TRIALS | MEDICINE, GENERAL & INTERNAL | GEFITINIB | EML4-ALK FUSION GENE | MUTATION | ACQUIRED-RESISTANCE | CRIZOTINIB | CLINICAL RESISTANCE | KINASE INHIBITOR | STI-571 | EGFR | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Sulfones - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Recombination, Genetic | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Treatment Outcome | Sulfones - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Maximum Tolerated Dose | Receptor Protein-Tyrosine Kinases - genetics | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Sulfones - administration & dosage | Antimitotic agents | Care and treatment | Dosage and administration | Research | Lung cancer, Non-small cell | Antineoplastic agents | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Insulin-like growth factors | Dehydration | Kinases | Patients | Lymphoma | Gene amplification | Vomiting | Gene rearrangement | Hypophosphatemia | Antitumor activity | Mutation | Pharmaceutical industry | Protein-tyrosine kinase | Tumors
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 9/2014, Volume 74, Issue 3, pp. 437 - 446
Journal Article
Expert opinion on biological therapy, 07/2019, p. 1
: Groundbreaking progress in cancer immunotherapy in the recent years has revolutionized the field of oncology with unprecedented survival rates in multiple... 
Journal Article
Therapeutic Advances in Respiratory Disease, ISSN 1753-4658, 10/2015, Volume 9
Research over the last decade has determined that the gene rearrangement involving the anaplastic lymphoma kinase ( ALK ) gene is an oncogenic driver in... 
Journal Article
British Journal of Cancer, ISSN 0007-0920, 07/2018, Volume 119, Issue 2, pp. 153 - 159
Journal Article
by Cohen, Ezra E W and Cohen, Ezra and Soulières, Denis and Le Tourneau, Christophe and Dinis, Jose and Dinis, José and Licitra, Lisa and Ahn, Myung-Ju and Soria, Ainara and Machiels, Jean-Pascal and Mach, Nicolas and Mehra, Ranee and Burtness, Barbara Ann and Burtness, Barbara and Zhang, Pingye and Cheng, Jonathan and Swaby, Ramona F and Harrington, Kevin and Harrington, Kevin J and Acosta-Rivera, Mirelis and Adkins, Douglas R and Aghmesheh, Morteza and Airoldi, Mario and Aleknavicius, Eduardas and Al-Farhat, Yousuf and Algazi, Alain P and Almokadem, Salah and Alyasova, Anna and Bauman, Jessica R and Benasso, Marco and Berrocal, Alfonso and Bray, Victoria and Caponigro, Francesco and Castro, Ana and Cescon, Terrence P and Chan, Kelvin and Chaudhry, Arvind and Chauffert, Bruno and Csoszi, Tibor and De Boer, J.P and Delord, Jean-Pierre and Dietz, Andreas and Dupuis, Charlotte and Digue, Laurence and Erfan, Jozsef and Escobar Alvarez, Yolanda and Evans, Mererid and Fidler, Mary Jo and Forster, Martin David and Friesland, Signe and Ganti, Apar K and Geoffrois, Lionnel and Grant, Cliona and Gruenwald, Viktor and Hoffmann, Thomas and Horvai, Geza and Inciura, Arturas and Jang, Raymond and Jankowska, Petra and Jimeno, Antonio and Joseph, Mano and Juarez Ramiro, Alejandro and Karaszewska, Boguslawa and Kawecki, Andrzej and Keilholz, Ulrich and Keller, Ulrich and Kim, Sung-Bae and Kocsis, Judit and Kotecki, Nuria and Kozloff, Mark F and Lambea, Julio and Landherr, Laszlo and Lantsukhay, Yuri and Lazarev, Sergey Alexandrovich and Lee, Lip Way and Lifirenko, Igor Dmitrievich and Martincic, Danko and Matorin, Oleg Vladmirovhich and McGrath, Margaret and Misiukiewicz, Krzysztof and Morris, John C and Mufazalov, Fagim Fanisovich and Niu, Jiaxin and Pamoorthy Srinivasan, Devraj and Perez Segura, Pedro and Rauch, Daniel and Ribeiro, Maria Leonor and Rodriguez, Cristina and Rolland, Frederic and Russo, Antonio and Ruzsa, Agnes and Sanches, Frederico and Shin, Sang-Won and Shtiveland, Mikhail and Soulieres, Denis and Specenier, Pol and Szekanecz, Eva and Szota, Judit and van Herpen, Carla M.L and Velez-Cortes, Hector A and ... and Keynote-040 Investigators and KEYNOTE-040 investigators
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10167, pp. 156 - 167
There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour... 
CRITERIA | TRIAL | MEDICINE, GENERAL & INTERNAL | NIVOLUMAB | CANCER | CHEMOTHERAPY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Docetaxel - adverse effects | Humans | Middle Aged | Squamous Cell Carcinoma of Head and Neck - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Cetuximab - therapeutic use | Cetuximab - adverse effects | Docetaxel - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Squamous Cell Carcinoma of Head and Neck - drug therapy | Female | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Head and Neck Neoplasms - drug therapy | Kaplan-Meier Estimate | Disease Progression | Head and Neck Neoplasms - pathology | Methotrexate - adverse effects | Squamous Cell Carcinoma of Head and Neck - secondary | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cetuximab - administration & dosage | Methotrexate - administration & dosage | Aged | Methotrexate | Squamous cell carcinoma | Metastasis | Therapy | Toxicity | Perforation | Clinical trials | Oncology | Cancer therapies | Metastases | Skin cancer | Anticancer properties | Pembrolizumab | Randomization | Motivation | Platinum | Neck | Safety | Medical treatment | Fatigue | Hypothyroidism | Survival | Patients | Chemotherapy | Interactive systems | Large intestine | Head and neck cancer | Ligands | Tumors
Journal Article
Nature Communications, ISSN 2041-1723, 12/2018, Volume 9, Issue 1, pp. 741 - 14
A majority of cancers fail to respond to immunotherapy with antibodies targeting immune checkpoints, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) or... 
GROWTH-FACTOR-BETA | MULTIDISCIPLINARY SCIENCES | TRANSCRIPTION FACTOR FOXP3 | REGULATORY T-CELLS | MEDIATED SUPPRESSION | CTLA-4 | MECHANISMS | DIFFERENTIATION | TUMOR EVASION | BLOCKADE | EXPRESSION | Forkhead Transcription Factors - immunology | Receptors, Transforming Growth Factor beta - genetics | Receptors, Transforming Growth Factor beta - immunology | Breast Neoplasms - immunology | Humans | Th1 Cells - immunology | T-Lymphocytes, Regulatory - immunology | Breast Neoplasms - therapy | Lymphocytes, Tumor-Infiltrating | Melanoma - genetics | Immunotherapy | Antibodies - immunology | Female | Transforming Growth Factor beta - immunology | Antibodies - therapeutic use | CTLA-4 Antigen - genetics | CTLA-4 Antigen - immunology | Forkhead Transcription Factors - genetics | B7-H1 Antigen - genetics | B7-H1 Antigen - immunology | Animals | Breast Neoplasms - genetics | Transforming Growth Factor beta - genetics | Melanoma - immunology | Th17 Cells - immunology | Antibodies - genetics | Mice, Inbred NOD | Mice | Melanoma - therapy | Cohort Studies | PD-1 protein | Immunoregulation | CD8 antigen | Transforming growth factor | Antibodies | Paracrine signalling | Cytotoxicity | Lymphocytes T | Immunological tolerance | Anticancer properties | CTLA-4 protein | Traps | Immune checkpoint | Lymphocytes | PD-L1 protein | Antitumor activity | Ligands | Inhibition | Autocrine signalling | Cancer | Apoptosis
Journal Article